leisure time -WSS

leisure time

author：hotspot 2025-09-30 00:03:25 - browse：2

Electrocardiogram in the shape of the United States map — Adobe

The market for artificial intelligence in health care is about as transparent as a brick wall. New tools achieve impressive results in published studies. But it is often difficult to compare them head to head with similar products, or tell whether they will work on different kinds of patients.

A new company is promising to change that — if it can convince AI developers to expose their products to more rigorous testing.

Called Dandelion Health, the New York-based firm is launching a first-of-its-kind public service to evaluate AI products on independent data designed to root out weaknesses and reveal bias. The company said Wednesday its initial pilot program, to begin next month, will focus on testing algorithms that use electrocardiograms to predict heart conditions.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： California Joshua trees severely burned in massive wildfire

WSS

Judge in Trump's Jan. 6 case gives attorneys 2 weeks to propose trial date

Does Medicare's free annual wellness visit do any good?

Flash flooding emergencies prompt evacuations in Kentucky, Tennessee

Takeaways from AdvaMed, the largest medical devices conference

Lifetime voting ban for felony convictions struck down in Mississippi

Scientists find bacteria from stomach of ancient iceman

entertainment

leisure time

knowledge

New air purifier tech could be key to improving indoor air quality

Russian court extends detention of American musician

Moonlake's readout produced a cash windfall. Risks remain

Eat, drink, but be wary — 4 foods that interact with medications

Drug repurposing or repositioning? The language matters

Cancer cells are shown to suck energy source from immune cells

Guidelines to prevent youth baseball injuries need more muscle

Medicare to cover more brain scans related to Alzheimer’s drugs

Moonlake's readout produced a cash windfall. Risks remain

STAT Readout: Today's biotech news includes Sana and Amylyx

entertainment

Humana CEO Bruce Broussard to step down in 2024

Female surgeons have lower rates of long

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

European regulators consider appeal over Amylyx ALS drug

Rock icon Freddie Mercury pre

Eight reasons why you should get an updated Covid vaccine

explore

focus

Wikipedia

hotspot